The pharma company has decided to proceed with the evaluation of OctoPlus’ PolyActive technology for an additional product candidate in its pipeline.

Under the contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the client’s product candidate with OctoPlus’ proprietary drug delivery technology.

OctoPlus said that if the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.